The past decade has shown a marked increase in the use of high-throughput assays in clinical research into human cancer, including acute myeloid leukemia (AML). In particular, genome-wide gene expression profiling (GEP) using DNA microarrays has been extensively used for improved understanding of the diagnosis, prognosis, and pathobiology of this heterogeneous disease. This review discusses the progress that has been made, places the technologic limitations in perspective, and highlights promising future avenues.

Additional Metadata
Persistent URL dx.doi.org/10.1182/blood-2008-04-153239, hdl.handle.net/1765/27240
Citation
Wouters, B.J., Löwenberg, B., & Delwel, H.R.. (2009). A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. Blood, 113(2), 291–298. doi:10.1182/blood-2008-04-153239